Home » Stocks » Molecular Templates

Molecular Templates, Inc. (MTEM)

Stock Price: $11.82 USD -0.20 (-1.66%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 590.05M
Revenue (ttm) 20.87M
Net Income (ttm) -107.35M
Shares Out 45.71M
EPS (ttm) -2.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $11.82
Previous Close $12.02
Change ($) -0.20
Change (%) -1.66%
Day's Open 11.96
Day's Range 11.65 - 12.17
Day's Volume 189,466
52-Week Range 4.51 - 19.12

More Stats

Market Cap 590.05M
Enterprise Value 524.53M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.71M
Float 33.09M
EPS (basic) 2.6
EPS (diluted) -2.54
FCF / Share -1.24
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.60M
Short Ratio 2.88
Short % of Float 9.06%
Beta 1.53
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 28.28
PB Ratio 6.29
Revenue 20.87M
Operating Income -106.72M
Net Income -107.35M
Free Cash Flow -56.80M
Net Cash 65.51M
Net Cash / Share 1.31
Gross Margin -135.39%
Operating Margin -511.48%
Profit Margin -514.50%
FCF Margin -272.21%
ROA -38.66%
ROE -147.94%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.40*
(81.05% upside)
Low
20.0
Current: $11.82
High
25.0
Target: 21.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue22.2713.293.401.8876.9214.7212.505.870.06-
Revenue Growth67.63%291.31%80.59%-97.56%422.45%17.82%112.97%9362.9%--
Gross Profit22.2713.293.401.8876.9214.7212.505.870.06-
Operating Income-70.45-31.00-17.85-10.6226.93-31.25-26.02-20.00-30.04-23.91
Net Income-69.42-30.29-23.14-11.0343.82-21.58-28.42-71.14-25.65-18.68
Shares Outstanding37.7729.6011.400.216.395.495.264.934.173.06
Earnings Per Share1.861.022.11-59.045.94-5.39-5.39-14.41-6.16-6.16
EPS Growth82.35%-51.66%--------
Operating Cash Flow-25.24-4.47-14.26-9.03-38.00-27.7410.1529.91-23.85-22.38
Capital Expenditures-9.65-5.72-1.10-0.10-0.11-0.22-0.16-0.48-0.53-0.11
Free Cash Flow-34.89-10.19-15.37-9.13-38.11-27.969.9929.43-24.38-22.49
Cash & Equivalents12597.9658.911.7248.6858.6065.6770.8520.2915.17
Total Debt14.623.253.4812.88------
Net Cash / Debt11094.7055.43-11.1648.6858.6065.6770.8520.2915.17
Assets17414090.393.1053.6768.4010489.5222.4416.20
Liabilities71.1739.2513.1017.0312.8292.3712810317.9511.26
Book Value10310177.29-39.8140.85-23.98-23.48-13.854.484.94
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Molecular Templates, Inc.
Country United States
Employees 219
CEO Eric E. Poma

Stock Information

Ticker Symbol MTEM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MTEM

Description

Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates, Inc. is headquartered in Austin, Texas.